JP2011520877A - ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品 - Google Patents

ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品 Download PDF

Info

Publication number
JP2011520877A
JP2011520877A JP2011509442A JP2011509442A JP2011520877A JP 2011520877 A JP2011520877 A JP 2011520877A JP 2011509442 A JP2011509442 A JP 2011509442A JP 2011509442 A JP2011509442 A JP 2011509442A JP 2011520877 A JP2011520877 A JP 2011520877A
Authority
JP
Japan
Prior art keywords
ethyl
phenyl
bicyclo
cycloheptanecarbonyloxy
azonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011509442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520877A5 (enExample
Inventor
リチャード・ジェイムズ・ブル
ローナン・フォード
アンドリュー・メイザー
アントニオ・メーテ
キャサリン・ウィリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Original Assignee
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808710A external-priority patent/GB0808710D0/en
Priority claimed from GB0900563A external-priority patent/GB0900563D0/en
Application filed by Pulmagen Therapeutics Synergy Ltd, AstraZeneca AB filed Critical Pulmagen Therapeutics Synergy Ltd
Publication of JP2011520877A publication Critical patent/JP2011520877A/ja
Publication of JP2011520877A5 publication Critical patent/JP2011520877A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011509442A 2008-05-13 2009-05-12 ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品 Pending JP2011520877A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0808710A GB0808710D0 (en) 2008-05-13 2008-05-13 New combination 296
GB0808710.8 2008-05-13
GB0900563.8 2009-01-14
GB0900563A GB0900563D0 (en) 2009-01-14 2009-01-14 New combination
PCT/SE2009/050525 WO2009139708A1 (en) 2008-05-13 2009-05-12 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST

Publications (2)

Publication Number Publication Date
JP2011520877A true JP2011520877A (ja) 2011-07-21
JP2011520877A5 JP2011520877A5 (enExample) 2012-06-07

Family

ID=41318921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509442A Pending JP2011520877A (ja) 2008-05-13 2009-05-12 ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品

Country Status (11)

Country Link
US (1) US20110190309A1 (enExample)
EP (1) EP2315589A4 (enExample)
JP (1) JP2011520877A (enExample)
KR (1) KR20110010725A (enExample)
CN (2) CN102908624A (enExample)
AU (1) AU2009247021B2 (enExample)
BR (1) BRPI0912657A2 (enExample)
CA (1) CA2723909A1 (enExample)
MX (1) MX2010012019A (enExample)
RU (1) RU2010147881A (enExample)
WO (1) WO2009139708A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
JP4837800B2 (ja) 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
KR101845257B1 (ko) 2011-02-07 2018-04-04 삼성전자주식회사 이미지 센서

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048225A1 (en) * 2004-11-02 2006-05-11 Novartis Ag Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
JP2006525267A (ja) * 2003-05-02 2006-11-09 ノバルティス アクチエンゲゼルシャフト ムスカリン性ｍ３受容体と結合するキヌクリジン誘導体
JP2010509391A (ja) * 2006-11-14 2010-03-25 アストラゼネカ・アクチエボラーグ ムスカリン受容体アンタゴニストとしての（ヘテロ）アリールシクロヘプタンカルボン酸のキヌクリジン誘導体
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (enExample) * 1942-12-16
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US6223485B1 (en) * 1996-06-07 2001-05-01 Herman Miller, Inc. Wall panel system
KR20000029703A (ko) * 1996-07-29 2000-05-25 존 헤덴스트룀 아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
WO2002096855A2 (en) * 2001-04-03 2002-12-05 Aryx Therapeutics Anticholinergic compounds and methods of use
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
WO2008059239A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
JP4837800B2 (ja) * 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525267A (ja) * 2003-05-02 2006-11-09 ノバルティス アクチエンゲゼルシャフト ムスカリン性ｍ３受容体と結合するキヌクリジン誘導体
WO2006048225A1 (en) * 2004-11-02 2006-05-11 Novartis Ag Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
JP2010509391A (ja) * 2006-11-14 2010-03-25 アストラゼネカ・アクチエボラーグ ムスカリン受容体アンタゴニストとしての（ヘテロ）アリールシクロヘプタンカルボン酸のキヌクリジン誘導体
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Also Published As

Publication number Publication date
CN102088976A (zh) 2011-06-08
KR20110010725A (ko) 2011-02-07
AU2009247021B2 (en) 2012-06-07
US20110190309A1 (en) 2011-08-04
CN102908624A (zh) 2013-02-06
EP2315589A1 (en) 2011-05-04
RU2010147881A (ru) 2012-06-20
CN102088976B (zh) 2012-12-26
EP2315589A4 (en) 2013-09-11
MX2010012019A (es) 2011-03-04
BRPI0912657A2 (pt) 2016-01-26
AU2009247021A1 (en) 2009-11-19
CA2723909A1 (en) 2009-11-19
WO2009139708A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
JP5337054B2 (ja) ムスカリン受容体アンタゴニストとベータ−２−アドレナリン受容体アゴニストの組み合わせ
AU2013365742B2 (en) Autotaxin inhibitors
JP2011524897A (ja) β２−アドレナリン受容体活性の調節のための、４−ヒドロキシ−２−オキソ−２，３−ジヒドロ−１，３−ベンゾチアゾール−７−イル化合物を含む医薬組成物
JP2011520877A (ja) ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品
JP2011530587A (ja) ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品
WO2009154554A1 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
WO2009154555A1 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
JP2011530586A (ja) ムスカリン受容体アンタゴニストおよび第二活性成分を含む医薬品
JP6364545B2 (ja) 結晶性（２ｓ）−３−［（３ｓ，４ｓ）−３−［（１ｒ）−１−ヒドロキシエチル］−４−（４−メトキシ−３−｛［１−（５−メチルピリジン−２−イル）アゼチジン−３−イル］オキシ｝フェニル）−３−メチルピロリジン−１−イル］−３−オキソプロパン−１，２−ジオ−ル
JP2007530451A (ja) 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2009139707A1 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130618